Sarepta Therapeutics,, Inc. Common Stock SRPT
Analyst Ratings
- Consensus
- Hold — 7 Buy · 4 Hold · 5 Sell (16 analysts)
- Avg. Price Target
- $23.47 (+29.7% upside)
Key Stats
- Today's Range
- $17.69 – $18.26
- 50-Day Range
- $14.68 – $20.88
- 52-Week Range
- $10.41 – $25.32
- Volume
- 1.56 million shs
- Average Volume
- 3.07 million shs
- Market Cap
- $1.94 billion
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 1.27
- Price / Sales
- 0.98
Short Interest
- Short Interest
- 9.38%
- Days to Cover
- 8.68
Financials (TTM)
- Revenue
- $1.97 billion
- Net Income
- $-136,725,000
- Net Margin
- -6.93%
- Return on Equity
- -8.95%
- Debt-to-Equity
- 0.55
About Sarepta Therapeutics,, Inc. Common Stock
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
Related Stocks
Compare head-to-head: SRPT vs LLY·SRPT vs JNJ·SRPT vs ABBV·SRPT vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.